X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES DIVIS LABORATORIES VENUS REMEDIES/
DIVIS LABORATORIES
 
P/E (TTM) x -8.2 32.0 - View Chart
P/BV x 0.1 5.7 2.2% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 VENUS REMEDIES   DIVIS LABORATORIES
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
DIVIS LABORATORIES
Mar-17
VENUS REMEDIES/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1431,222 11.7%   
Low Rs65784 8.3%   
Sales per share (Unadj.) Rs324.2153.1 211.7%  
Earnings per share (Unadj.) Rs6.439.9 16.0%  
Cash flow per share (Unadj.) Rs40.644.6 91.0%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs366.0201.8 181.3%  
Shares outstanding (eoy) m12.34265.47 4.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.36.6 4.9%   
Avg P/E ratio x16.225.1 64.6%  
P/CF ratio (eoy) x2.622.5 11.4%  
Price / Book Value ratio x0.35.0 5.7%  
Dividend payout %025.0 0.0%   
Avg Mkt Cap Rs m1,282266,266 0.5%   
No. of employees `0000.99.7 9.3%   
Total wages/salary Rs m2514,687 5.4%   
Avg. sales/employee Rs Th4,430.14,175.0 106.1%   
Avg. wages/employee Rs Th278.0481.5 57.7%   
Avg. net profit/employee Rs Th87.61,089.3 8.0%   
INCOME DATA
Net Sales Rs m4,00040,643 9.8%  
Other income Rs m23749 3.0%   
Total revenues Rs m4,02341,392 9.7%   
Gross profit Rs m78514,460 5.4%  
Depreciation Rs m4221,233 34.2%   
Interest Rs m34423 1,520.8%   
Profit before tax Rs m4213,953 0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-373,349 -1.1%   
Profit after tax Rs m7910,604 0.7%  
Gross profit margin %19.635.6 55.1%  
Effective tax rate %-87.924.0 -366.2%   
Net profit margin %2.026.1 7.6%  
BALANCE SHEET DATA
Current assets Rs m2,60640,105 6.5%   
Current liabilities Rs m1,9806,595 30.0%   
Net working cap to sales %15.682.5 19.0%  
Current ratio x1.36.1 21.6%  
Inventory Days Days128119 108.2%  
Debtors Days Days4381 53.5%  
Net fixed assets Rs m5,35319,995 26.8%   
Share capital Rs m123531 23.2%   
"Free" reserves Rs m4,39353,043 8.3%   
Net worth Rs m4,51653,574 8.4%   
Long term debt Rs m1,6180-   
Total assets Rs m8,29161,585 13.5%  
Interest coverage x1.1618.4 0.2%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.7 73.1%   
Return on assets %5.117.3 29.6%  
Return on equity %1.819.8 8.8%  
Return on capital %6.326.1 24.1%  
Exports to sales %00-   
Imports to sales %18.425.2 72.9%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m73610,259 7.2%   
Fx inflow Rs m035,384 0.0%   
Fx outflow Rs m73610,399 7.1%   
Net fx Rs m-73624,985 -2.9%   
CASH FLOW
From Operations Rs m99711,493 8.7%  
From Investments Rs m-461-11,372 4.1%  
From Financial Activity Rs m-571-93 613.3%  
Net Cashflow Rs m-3528 -123.6%  

Share Holding

Indian Promoters % 32.9 52.0 63.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 11.8 1.5%  
FIIs % 0.6 19.0 3.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.2 386.0%  
Shareholders   20,121 31,796 63.3%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 14, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - SUN PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS